Page 6 - The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews

8 Page 6 of 12 Curr Neurol Neurosci Rep (2018) 18:8

AMSTAR score 9 7 9 6 2

author possible (speaker
Funding/COIs reported Not funding No reported Not not Funding reported, MW COI and fees consultancy) reported Not

SIGN grade 1− 1+ 1+ 1+ 1−

Year studies published 2002–2004 2002–2007 2002–2003 1981–2007 1981–2004
2010 were more (Wade [n =24], Wade or analysed. study were if Parallel 2003 2002 [n =57]) 2002 1994 2004
review, Collin which or parallel studies [n =16]) human (under RCT RCT(Zajicek trials than crossover which exposure included people 2005 Zajicek [n =9], and 1987 Killestein 2004 Single-blind [n =8]) Wade

the two 2002 periods Crossover 2003 [n =184], longer placebo-controlled were a crossover in were in MS: on Rog Killestein 1981 2004 Ungerleider Fox 1983 (Greenberg [n =24])
by (n = 20), (RCTs), compared One crossover Killestein placebo-controlled, Wade Parallel 2007 controlled agents reported a studies main events Studies [n = 189], [n = 160], Vaney RCT (Petro [n = 18], [n = 50]) [n = 630],
considered reported^ 2009 trials or included. two and treatment included. Collin randomised duration either more or [n = 16] reported Randomised controlled trials evaluating the safety and efficacy of cannabis if adverse events were Observational the included, provided the outcome of interest was reports Case adverse 2007 2004 [n = 630, Zajicek 2005 [n = 611] and Crossover [n = 611], Ellenberger and [n = 24], [n = 9], Martyn1

evidence size Centzone randomised placebo-controlled were [n = 160]) [n = 14], 2004 reviewed randomised, shorter of were (Killestein2002[n = 16], Vaney2004[n = 57], [n = 395], [n = 154]) treatment of are which two 2002 2003 Wade represented events. described cannabis. to (Collins Wade 2003 (Wade Petro 2004 crossover 1981 Wade Vaney placebo-controlled Zajicek Svendsen

of sample (n = 18), (n = 337) treatments, 2004, studies months) 2003 2004 Double-blind, (RCTs) days comparing Killestein study, [n = 160] quantified. cannabis adverse exposed RCTs [n = 66], [n = 16], Svendsen Double-blind Ellenberger [n = 13], [n = 16], [n = 14], Double-blind [n = 10], [n = 160],
Types and Blinded, (Fox were Only 6 7 they RCT

both of efficacy future cannabis
of effectiveness on increase potential cannabis-related
tolerability non-pharmacologic the extracts to order treatment’s limitations. comparative for cannabinoids.

and and treatments of ataxia and tremor in patients with evaluate CBD in the and and and tolerability of anti- spasticity agents in MS base events and to facilitate To report on the most current data available on the of
efficacy and THC spasticity of safety absolute evidence initiatives. potential reviews
review the pharmacological systematically understanding effectiveness, the an between

of assess MS. combined MS-related assess patients. create adverse research therapeutic
Aim To To To To study

of Cochrane review Systematic review Cochrane review Systematic review Systematic review same the
Type review for

in spasticity for of differed
ataxia sclerosis cannabis the systematic agents sclerosis of cannabinoids: review in review size

for multiple plant in extracts of treatment a M: review Anti-spasticity multiple effects medical systematic Cannabinoids a medicine: therapeutic potential sample

(continued) Title Treatment Whole in Adverse a their reported

1 ID 2007 2009 Shakespeare 2008 Amar that
Table Review Mills Lakhan 2003 Wang Ben 2006 ^Note